DK1994005T3 - Tetrahydronaphthalinderivater, fremgangsmåde til fremstilling heraf og anvendelse heraf som betændelseshæmmere - Google Patents

Tetrahydronaphthalinderivater, fremgangsmåde til fremstilling heraf og anvendelse heraf som betændelseshæmmere

Info

Publication number
DK1994005T3
DK1994005T3 DK07723399.7T DK07723399T DK1994005T3 DK 1994005 T3 DK1994005 T3 DK 1994005T3 DK 07723399 T DK07723399 T DK 07723399T DK 1994005 T3 DK1994005 T3 DK 1994005T3
Authority
DK
Denmark
Prior art keywords
preparation
tetrahydronaphthalene derivatives
inflammatory inhibitors
inflammatory
inhibitors
Prior art date
Application number
DK07723399.7T
Other languages
English (en)
Inventor
Markus Berger
Hartmut Rehwinkel
Heike Schaecke
Stefan Baeurle
Norbert Schmees
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36754173&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1994005(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of DK1994005T3 publication Critical patent/DK1994005T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C15/00—Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic parts
    • C07C15/20—Polycyclic condensed hydrocarbons
    • C07C15/24—Polycyclic condensed hydrocarbons containing two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
DK07723399.7T 2006-03-15 2007-03-15 Tetrahydronaphthalinderivater, fremgangsmåde til fremstilling heraf og anvendelse heraf som betændelseshæmmere DK1994005T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06090031A EP1834948A1 (de) 2006-03-15 2006-03-15 Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
US78444106P 2006-03-22 2006-03-22
PCT/EP2007/002432 WO2007104582A1 (de) 2006-03-15 2007-03-15 Tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer

Publications (1)

Publication Number Publication Date
DK1994005T3 true DK1994005T3 (da) 2011-11-21

Family

ID=36754173

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07723399.7T DK1994005T3 (da) 2006-03-15 2007-03-15 Tetrahydronaphthalinderivater, fremgangsmåde til fremstilling heraf og anvendelse heraf som betændelseshæmmere

Country Status (35)

Country Link
US (2) US7880042B2 (da)
EP (2) EP1834948A1 (da)
JP (1) JP2009532337A (da)
KR (1) KR20080112233A (da)
CN (1) CN101553472A (da)
AR (1) AR059896A1 (da)
AT (1) ATE517092T1 (da)
AU (1) AU2007224593A1 (da)
BR (1) BRPI0708860A2 (da)
CA (1) CA2637597A1 (da)
CR (1) CR10286A (da)
CU (1) CU23744B7 (da)
CY (1) CY1111954T1 (da)
DK (1) DK1994005T3 (da)
DO (1) DOP2007000050A (da)
EA (1) EA015834B1 (da)
EC (1) ECSP088740A (da)
ES (1) ES2370176T3 (da)
GT (1) GT200800182A (da)
IL (1) IL193155A0 (da)
MX (1) MX2008011790A (da)
MY (1) MY146671A (da)
NO (1) NO20084301L (da)
NZ (1) NZ570407A (da)
PA (1) PA8718801A1 (da)
PE (1) PE20071024A1 (da)
PL (1) PL1994005T3 (da)
PT (1) PT1994005E (da)
SG (1) SG136072A1 (da)
SI (1) SI1994005T1 (da)
TW (1) TW200804287A (da)
UA (1) UA94603C2 (da)
UY (1) UY30211A1 (da)
WO (1) WO2007104582A1 (da)
ZA (1) ZA200808754B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638515B2 (en) * 2003-10-08 2009-12-29 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US7662821B2 (en) 2003-10-08 2010-02-16 Bayer Schering Pharma Ag Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
PL1670458T3 (pl) * 2003-10-08 2007-05-31 Bayer Schering Pharma Ag 1-amino-2-hydroksy-podstawione pochodne tetrahydronaftalenu, sposób ich wytwarzania i ich zastosowanie jako środków hamujących zapalenie
US20080153859A1 (en) * 2004-04-05 2008-06-26 Hartmut Rehwinkel Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US20060084652A1 (en) * 2004-09-09 2006-04-20 Stefan Baeurle Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US20060229305A1 (en) * 2005-03-22 2006-10-12 Markus Berger Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
EP2072509A1 (en) * 2007-12-18 2009-06-24 Bayer Schering Pharma Aktiengesellschaft 1-Aryl-1H-quinoline-2-ones: process for their production and their use as anti-inflammatory agents
WO2011146610A2 (en) * 2010-05-19 2011-11-24 Dr. Reddy's Laboratories Ltd. An enantioselective synthesis of chiral amines for the production of rotigotine
JP6115303B2 (ja) * 2012-05-18 2017-04-19 Jnc株式会社 隣接基としてカルボニル基を有するフェノール化合物およびその用途
PL233977B1 (pl) * 2018-01-10 2019-12-31 Politechnika Warszawska Sposób otrzymywania 7-metoksy-1,2,3-tris(4-metoksyfenylo)- 1,2,3,4-tetrahydronaftalenu

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791474A (fr) 1971-11-25 1973-03-16 Yamanouchi Pharma Co Ltd Procede de preparation de derives d'acides cycloalcoylaminoarylcarboxyliques
JPS63220242A (ja) 1987-03-10 1988-09-13 Fuji Photo Film Co Ltd フオトレジスト組成物
US5225436A (en) 1987-05-15 1993-07-06 Schering Corporation Aryl substituted naphthalene derivatives
WO1988008836A2 (en) 1987-05-15 1988-11-17 Schering Corporation Aryl substituted naphthalene, benzoxepine, benzazepine, benzocycloheptene derivatives
WO1989000570A1 (en) 1987-07-16 1989-01-26 Byk Gulden Lomberg Chemische Fabrik Gmbh New diazols
US5059609A (en) 1987-10-19 1991-10-22 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases
JPH0717589B2 (ja) 1990-01-22 1995-03-01 ファイザー製薬株式会社 新規１，３―ジカルボニル化合物およびその組成物
JPH0641038A (ja) 1992-07-17 1994-02-15 Mitsubishi Kasei Corp カルボン酸誘導体
CA2208844A1 (en) 1994-12-29 1996-07-11 Alan T. Johnson Acetylenes disubstituted with a 5 or 8 substituted tetrahydronaphthyl or dihydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
US5489584A (en) 1994-12-29 1996-02-06 Allergan, Inc. Acetylenes disubstituted with a 5-amino or substituted 5-amino substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
EA002402B1 (ru) 1997-03-24 2002-04-25 Бык Гульден Ломберг Хемише Фабрик Гмбх Тетрагидропиридо-соединения
AU8591898A (en) 1997-07-22 1999-02-16 Eli Lilly And Company Pharmaceutical compounds
GB9716244D0 (en) 1997-07-31 1997-10-08 Electrophoretics International Pharmaceutical compounds
US6333337B1 (en) 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
US7468422B2 (en) * 1998-03-05 2008-12-23 Centre National De La Recherche Scientifique - Cnrs Mechanosensitive mammalian potassium channel activatable by polyunsaturated fatty acids
US6013830A (en) 1998-03-30 2000-01-11 Sepracor Inc. Asymmetric grignard synthesis with cyclic 1,2 aminoalcohols
AU5682299A (en) 1998-08-21 2000-03-14 Scripps Research Institute, The Catalytic asymmetric aminohydroxylation with amino-substituted heterocycles
JP2000256255A (ja) 1999-03-10 2000-09-19 Kuraray Co Ltd （±）−トランス−ペルメトリン酸の光学分割法
SE9903930D0 (sv) 1999-10-29 1999-10-29 Astra Pharma Inc Novel compounds and a novel process for their preparation
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
AU2001280229B2 (en) 2000-08-21 2006-12-07 Pacific Corporation Novel thiourea derivatives and the pharmaceutical compositions containing the same
ES2193839B1 (es) 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
CA2461218C (en) 2001-09-21 2011-02-01 Eli Lilly And Company Muscarinic agonists
UY27450A1 (es) 2001-09-24 2003-04-30 Bayer Corp Preparación y uso de derivados de imidazol para el tratamiento de la obesidad
ES2333586T3 (es) 2001-11-21 2010-02-24 PHARMACIA & UPJOHN COMPANY LLC Derivados de aril 1,4-pirazina sustituidos.
US6875866B2 (en) 2002-02-21 2005-04-05 Schering Corporation Process for synthesis of D1 receptor antagonists
EP1497300A2 (en) 2002-03-21 2005-01-19 Schering Aktiengesellschaft Plasma carboxypeptidase b inhibitors
CN1633296A (zh) 2002-03-26 2005-06-29 贝林格尔·英格海姆药物公司 糖皮质素模拟物、其制备方法、药物组合物及其用途
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
US6897224B2 (en) 2002-04-02 2005-05-24 Schering Ag Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors
AU2003258538A1 (en) 2002-08-26 2004-03-19 Merck Patent Gmbh Cyclopenta(b)naphthalene derivatives
KR20050109922A (ko) 2003-01-03 2005-11-22 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 1-프로판올과 1-프로필아민 유도체 및 글루코코르티코이드리간드로서의 이들의 용도
US20040224992A1 (en) 2003-02-27 2004-11-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EA200600148A1 (ru) 2003-07-01 2006-08-25 Шеринг Акциенгезельшафт Гетероциклически замещённые производные пентанола, способ их получения и их применение в качестве ингибиторов воспаления
US20050090559A1 (en) 2003-07-01 2005-04-28 Markus Berger Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents
US7575785B2 (en) 2003-08-22 2009-08-18 Merck Patent Gmbh Cyclopenta[a]naphthaline derivatives
CN1239441C (zh) 2003-09-12 2006-02-01 中国科学院上海有机化学研究所 利用固载化的双辛可尼类生物碱配体催化不对称羟胺化和双羟化反应的方法
US7662821B2 (en) 2003-10-08 2010-02-16 Bayer Schering Pharma Ag Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US7638515B2 (en) * 2003-10-08 2009-12-29 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
PL1670458T3 (pl) * 2003-10-08 2007-05-31 Bayer Schering Pharma Ag 1-amino-2-hydroksy-podstawione pochodne tetrahydronaftalenu, sposób ich wytwarzania i ich zastosowanie jako środków hamujących zapalenie
US7179919B2 (en) 2004-03-18 2007-02-20 Boehringer Ingelheim Pharmaceuticals, Inc. Stereoselective synthesis of certain trifluoromethyl-substituted alcohols
US20080153859A1 (en) 2004-04-05 2008-06-26 Hartmut Rehwinkel Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US20050222154A1 (en) 2004-04-05 2005-10-06 Hartmut Rehwinkel Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
US20060084652A1 (en) 2004-09-09 2006-04-20 Stefan Baeurle Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
DE102004044680B3 (de) 2004-09-09 2006-06-08 Schering Ag Alkyliden-Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer sowie diese enthaltende pharmazeutische Präparate
US20060167025A1 (en) 2004-12-22 2006-07-27 Markus Berger Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs
DE102004063227A1 (de) 2004-12-22 2006-07-06 Schering Ag Tricylische Aminoalkohole, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
DE102005014089A1 (de) 2005-03-22 2006-09-28 Schering Ag Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
US20060229305A1 (en) 2005-03-22 2006-10-12 Markus Berger Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US20060247292A1 (en) * 2005-03-22 2006-11-02 Hartmut Rehwinkel Benzocycloheptene derivatives, process for their production and their use as anti-inflammatory agents
DE102005017286B3 (de) 2005-04-14 2006-12-28 Schering Ag Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
US20070015761A1 (en) 2005-04-14 2007-01-18 Anne Mengel Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US20070129359A1 (en) 2005-04-14 2007-06-07 Christoph Huwe Tetrahydronaphthalene derivatives, processes for their preparation and their use as antiinflammatory agents
US8093281B2 (en) 2005-04-14 2012-01-10 Glaxo Group Limited Indazoles as glucocorticoid receptor ligands
US20070015750A1 (en) 2005-04-14 2007-01-18 Stefan Baeurle Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
CN101326169B (zh) 2005-12-09 2011-11-16 霍夫曼-拉罗奇有限公司 作为抗炎剂的糖皮质激素受体调节剂

Also Published As

Publication number Publication date
CN101553472A (zh) 2009-10-07
MY146671A (en) 2012-09-14
EP1994005B1 (de) 2011-07-20
CR10286A (es) 2008-10-29
EP1994005B9 (de) 2012-01-11
EP1994005A1 (de) 2008-11-26
CU23744B7 (es) 2012-01-31
PA8718801A1 (es) 2009-04-23
US7880042B2 (en) 2011-02-01
US20100298311A1 (en) 2010-11-25
DOP2007000050A (es) 2007-09-30
TW200804287A (en) 2008-01-16
ES2370176T3 (es) 2011-12-13
GT200800182A (es) 2009-08-20
WO2007104582A1 (de) 2007-09-20
UY30211A1 (es) 2007-10-31
PL1994005T3 (pl) 2012-01-31
SG136072A1 (en) 2007-10-29
KR20080112233A (ko) 2008-12-24
MX2008011790A (es) 2008-09-25
PE20071024A1 (es) 2007-12-13
IL193155A0 (en) 2009-02-11
SI1994005T1 (sl) 2011-11-30
ZA200808754B (en) 2009-12-30
NZ570407A (en) 2010-08-27
CA2637597A1 (en) 2007-09-20
US20070225290A1 (en) 2007-09-27
EA200801893A1 (ru) 2009-04-28
ECSP088740A (es) 2008-10-31
AR059896A1 (es) 2008-05-07
UA94603C2 (ru) 2011-05-25
AU2007224593A1 (en) 2007-09-20
JP2009532337A (ja) 2009-09-10
EA015834B1 (ru) 2011-12-30
CY1111954T1 (el) 2015-11-04
BRPI0708860A2 (pt) 2011-06-14
EP1834948A1 (de) 2007-09-19
PT1994005E (pt) 2011-10-20
CU20080169A7 (es) 2011-02-24
NO20084301L (no) 2008-12-12
ATE517092T1 (de) 2011-08-15

Similar Documents

Publication Publication Date Title
LTC1907382I2 (lt) Nitrokatechnolio dariniai, kaip COMT inhibitoriai
DK1994005T3 (da) Tetrahydronaphthalinderivater, fremgangsmåde til fremstilling heraf og anvendelse heraf som betændelseshæmmere
DK2049557T3 (da) 1-(-D-glycopyranosyl)-3-(4-cyclopropylphenylmethyl)-4-halogenindolderivater og anvendelse heraf som sglt-inhibitorer
DK2094263T3 (da) 2-adamantyl-butyramidderivater som selektive 11 beta-hsd1-inhibitorer
DK2099447T3 (da) Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer
DK1960352T3 (da) 2-adamantylurinstof-derivater som selektive 11beta-hsd1 inhibitorer
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
DK2200588T3 (da) Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf
DK2121614T3 (da) Aminonikotin og isonikotinsyrederivater som dhodh-inhibitorer
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
DK2078001T3 (da) Diazepan-acetamidderivater som selektive 11-HSD1-inhibitorer
DK1846394T3 (da) Pyrazolylaminopyridinderivater, der er egnede som kinaseinhibitorer
DK2074122T5 (da) Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer
NO20091424L (no) Substituerte amider, fremgangsmåte for fremstilling derav og anvendelse derav
NO20091426L (no) Substituerte amider, fremgangsmåte for fremstilling derav og anvendelse derav
DK2066324T3 (da) Cycloalkanpyrrolocarbazolderivater og anvendelse deraf som parp, vegfr2 og mlk3 inhibitorer
DK3428148T3 (da) Aryloazol-2-yl-cyanoethylaminoforbindelser, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf
DK2178840T3 (da) Azabiphenylaminobenzoesyre-derivater som dhodh-hæmmere
DK2069324T3 (da) Fusioneret aminopyridin som hsp90-inhibitorer
DK1981892T3 (da) Thienopyridinderivater som mek-inhibitorer
DK2044076T3 (da) Fremgangsmåde til fremstilling af asenapin og intermediatprodukter, som anvendes i fremgangsmåden
DK1926722T3 (da) Substituerede benzimidazoler som kinaseinhibitorer
DK2220070T3 (da) 2-benzylpyridazinonderivater som Met-kinaseinhibitorer
DK1868999T3 (da) Pyridin-3-carboxamidderivater som omvendte CB1-agonister